# Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)

> **NCT01135615** · PHASE4 · COMPLETED · sponsor: **Gulhane School of Medicine** · enrollment: 100 (actual)

## Conditions studied

- We Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients.

## Interventions

- **DRUG:** Sevelamer
- **DRUG:** calcium acetate

## Key facts

- **NCT ID:** NCT01135615
- **Lead sponsor:** Gulhane School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-04
- **Final completion:** 2010-05
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2011-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01135615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01135615, "Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01135615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*